Cargando…

Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation

We evaluated the prognostic value of fluorine‐18 fluorodeoxyglucose ((18)F‐FDG) positron emission tomography/computed tomography (PET/CT) in hepatocellular carcinoma (HCC). Their association with programmed death ligand 1 (PD‐L1) expression and vascular formation was further investigated. In this re...

Descripción completa

Detalles Bibliográficos
Autores principales: Itoh, Shinji, Yoshizumi, Tomoharu, Kitamura, Yoshiyuki, Yugawa, Kyohei, Iseda, Norifumi, Shimagaki, Tomonari, Nagao, Yoshihiro, Toshima, Takeo, Harada, Noboru, Kohashi, Kenichi, Baba, Shingo, Ishigami, Kousei, Oda, Yoshinao, Mori, Masaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279470/
https://www.ncbi.nlm.nih.gov/pubmed/34278175
http://dx.doi.org/10.1002/hep4.1715
_version_ 1783722462254465024
author Itoh, Shinji
Yoshizumi, Tomoharu
Kitamura, Yoshiyuki
Yugawa, Kyohei
Iseda, Norifumi
Shimagaki, Tomonari
Nagao, Yoshihiro
Toshima, Takeo
Harada, Noboru
Kohashi, Kenichi
Baba, Shingo
Ishigami, Kousei
Oda, Yoshinao
Mori, Masaki
author_facet Itoh, Shinji
Yoshizumi, Tomoharu
Kitamura, Yoshiyuki
Yugawa, Kyohei
Iseda, Norifumi
Shimagaki, Tomonari
Nagao, Yoshihiro
Toshima, Takeo
Harada, Noboru
Kohashi, Kenichi
Baba, Shingo
Ishigami, Kousei
Oda, Yoshinao
Mori, Masaki
author_sort Itoh, Shinji
collection PubMed
description We evaluated the prognostic value of fluorine‐18 fluorodeoxyglucose ((18)F‐FDG) positron emission tomography/computed tomography (PET/CT) in hepatocellular carcinoma (HCC). Their association with programmed death ligand 1 (PD‐L1) expression and vascular formation was further investigated. In this retrospective study, using a database of 418 patients who had undergone (18)F‐FDG PET/CT before hepatic resection for HCC, immunohistochemical staining of PD‐L1, clusters of differentiation (CD) 8, CD68, and CD34 was performed. Patients with a high maximum standardized uptake value (SUVmax) on (18)F‐FDG PET/CT showed a significantly worse recurrence‐free survival (RFS) (hazard ratio [HR]: 1.500; 95% confidence interval [CI]: 1.088‐2.069; P = 0.0133) and overall survival (OS) (HR: 2.259; 95% CI: 1.276‐4.000; P = 0.0052) than patients with a low SUVmax. Logistic regression analysis showed that a high SUVmax in HCC was significantly associated with PD‐L1‐positive expression (odds ratio: 4.407; 95% CI: 2.265‐8.575; P < 0.0001). SUVmax values of HCC were associated with intratumoral CD8‐positive T‐cell counts (P = 0.0044) and CD68‐positive macrophage counts (P = 0.0061). Stratification based on SUVmax, PD‐L1 expression, and the vessels that encapsulate tumor clusters (VETC) status was also significantly associated with RFS and OS. SUVmax, VETC, and PDL1 expression were independently predictive of survival on multivariable analysis. Conclusion: Our large cohort study showed that a high SUVmax on (18)F‐FDG PET/CT is associated with a poor clinical outcome and PD‐L1 expression in patients with HCC. Additionally, stratification of patients based on the combination of SUVmax, PD‐L1 expression, and the VETC status predicts poor clinical outcome.
format Online
Article
Text
id pubmed-8279470
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82794702021-07-15 Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation Itoh, Shinji Yoshizumi, Tomoharu Kitamura, Yoshiyuki Yugawa, Kyohei Iseda, Norifumi Shimagaki, Tomonari Nagao, Yoshihiro Toshima, Takeo Harada, Noboru Kohashi, Kenichi Baba, Shingo Ishigami, Kousei Oda, Yoshinao Mori, Masaki Hepatol Commun Original Articles We evaluated the prognostic value of fluorine‐18 fluorodeoxyglucose ((18)F‐FDG) positron emission tomography/computed tomography (PET/CT) in hepatocellular carcinoma (HCC). Their association with programmed death ligand 1 (PD‐L1) expression and vascular formation was further investigated. In this retrospective study, using a database of 418 patients who had undergone (18)F‐FDG PET/CT before hepatic resection for HCC, immunohistochemical staining of PD‐L1, clusters of differentiation (CD) 8, CD68, and CD34 was performed. Patients with a high maximum standardized uptake value (SUVmax) on (18)F‐FDG PET/CT showed a significantly worse recurrence‐free survival (RFS) (hazard ratio [HR]: 1.500; 95% confidence interval [CI]: 1.088‐2.069; P = 0.0133) and overall survival (OS) (HR: 2.259; 95% CI: 1.276‐4.000; P = 0.0052) than patients with a low SUVmax. Logistic regression analysis showed that a high SUVmax in HCC was significantly associated with PD‐L1‐positive expression (odds ratio: 4.407; 95% CI: 2.265‐8.575; P < 0.0001). SUVmax values of HCC were associated with intratumoral CD8‐positive T‐cell counts (P = 0.0044) and CD68‐positive macrophage counts (P = 0.0061). Stratification based on SUVmax, PD‐L1 expression, and the vessels that encapsulate tumor clusters (VETC) status was also significantly associated with RFS and OS. SUVmax, VETC, and PDL1 expression were independently predictive of survival on multivariable analysis. Conclusion: Our large cohort study showed that a high SUVmax on (18)F‐FDG PET/CT is associated with a poor clinical outcome and PD‐L1 expression in patients with HCC. Additionally, stratification of patients based on the combination of SUVmax, PD‐L1 expression, and the VETC status predicts poor clinical outcome. John Wiley and Sons Inc. 2021-03-26 /pmc/articles/PMC8279470/ /pubmed/34278175 http://dx.doi.org/10.1002/hep4.1715 Text en © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Itoh, Shinji
Yoshizumi, Tomoharu
Kitamura, Yoshiyuki
Yugawa, Kyohei
Iseda, Norifumi
Shimagaki, Tomonari
Nagao, Yoshihiro
Toshima, Takeo
Harada, Noboru
Kohashi, Kenichi
Baba, Shingo
Ishigami, Kousei
Oda, Yoshinao
Mori, Masaki
Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation
title Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation
title_full Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation
title_fullStr Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation
title_full_unstemmed Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation
title_short Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation
title_sort impact of metabolic activity in hepatocellular carcinoma: association with immune status and vascular formation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279470/
https://www.ncbi.nlm.nih.gov/pubmed/34278175
http://dx.doi.org/10.1002/hep4.1715
work_keys_str_mv AT itohshinji impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT yoshizumitomoharu impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT kitamurayoshiyuki impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT yugawakyohei impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT isedanorifumi impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT shimagakitomonari impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT nagaoyoshihiro impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT toshimatakeo impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT haradanoboru impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT kohashikenichi impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT babashingo impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT ishigamikousei impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT odayoshinao impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation
AT morimasaki impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation